The Outcome

VERIGRAFT was granted € 2.2M from the SME Instrument, HORIZON 2020, phase 2.

The Company

VERIGRAFT is an innovative and independent biotech company located in Gothenburg, Sweden. The company is present in the field of regenerative medicine by developing personalized human tissues for transplantation. The current focus area is the development of fully biological, personalized blood vessels that can be used to replace diseased or non-functioning blood vessels in patients. With unique, patented and improved alternative to existing treatments, VERIGRAFT strives to deliver a life changing impact to patients and provide major benefits for hospitals, healthcare providers and society – globally.

The project

Part of the development of  VERIGRAFT’s personalized tissue-engineered vein, P-TEV,  product is supported by the SME instrument grant under the Horizon 2020 program. This funding supports the Phase I/II clinical development of VERIGRAFT’s lead product. P-TEV has gone through preclinical development at the company. Safety data from large animals has been generated. Clinical proof-of-concept in humans exists. The product is planned to enter clinical development within 6 months.

GAEU's role

We guided the client throughout the entire process, and helped by optimizing the budget. We also assisted the team in creating a long-term clinical development plan for the project.


“The SME Instrument funding represents an important element on our way to the next level of development and we are very proud to have been promoted to the SME Champions league. The VERIGRAFT team is very thankful for this reward of our rock-solid commitment and we are highly motivated to make this project a great success. This funding will facilitate our high ambitions to develop novel products that can help millions of patients with today incurable diseases.”

Dr. Petter Björquist, CEO, VERIGRAFT